title: Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98).
authors.affiliation: Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Southampton, UK.
authors.forename: Chern Siang
authors.initials: CS
authors.lastname: Lee
authors.forename: Margaret
authors.initials: M
authors.lastname: Ashton-Key
authors.forename: Sergio
authors.initials: S
authors.lastname: Cogliatti
authors.forename: Stephanie
authors.initials: S
authors.lastname: Rondeau
authors.forename: Shu-Fang Hsu
authors.initials: SF
authors.lastname: Schmitz
authors.forename: Michele
authors.initials: M
authors.lastname: Ghielmini
authors.forename: Mark S
authors.initials: MS
authors.lastname: Cragg
authors.forename: Peter
authors.initials: P
authors.lastname: Johnson
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015870:Gene Expression; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000235:genetics*; D017452:Receptors, IgG / Q000235:genetics*; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; C499173:FCGR2B protein, human; D017452:Receptors, IgG; D000069283:Rituximab
keywords: Fc receptor; antibody therapy; biomarker; non-hodgkin lymphoma; rituximab